6. Bibliografía

-Sarhane KA, Ibrahim A, Fagan SP, Goverman J. Phytophotodermatitis. Eplasty. 2013; 13:ic57.

-Harshman J, Quan Y, Hsiang D. Phytophotodermatitis: Rash with many faces. Can Fam Physician. 2017; 63:938-940.

-Son JH, Jin H, You HS, Shim WH, Kim JM, Kim GW, Kim HS, Ko HC, Kim MB, Kim BS. Five Cases of Phytophotodermatitis Caused by Fig Leaves and Relevant Literature Review. Ann Dermatol. 2017; 29:86-90.

-Choi JY, Hwang S, Lee SH, Oh SH. Asymptomatic Hyperpigmentation without Preceding Inflammation as a Clinical Feature of Citrus Fruits-Induced Phytophotodermatitis. Ann Dermatol. 2018; 30:75-78.

Hoetzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016; 38:75-86.

-Carneiro SC, Azevedo-e-Silva MC, Ramos-e-Silva M. Drug eruptions in the elderly. Clin Dermatol. 2011; 29:43-8.

-Young JWS, Shear NH. Cutaneous Drug Reactions in the Elderly. Drugs Aging. 2017; 34:655-672.

-Papakonstantinou E, Müller S, Röhrbein JH, Wieczorek D, Kapp A, Jakob T, Wedi B. Generalized reactions during skin testing with clindamycin in drug hypersensitivity: a report of 3 cases and review of the literature. Contact Dermatitis. 2018; 78:274-280.

-Trautmann A, Benoit S, Goebeler M, Stoevesandt J. “Treating Through” Decision and Follow-up in Antibiotic Therapy-Associated Exanthemas. J Allergy Clin Immunol Pract. 2017; 5:1650-1656.

-Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, Machet L, Amsler E, Claeys A, Sassolas B, Leroy D, Grange A, Dupuy A, Cordel N, Bonnetblanc JM, Milpied B, Doutre MS, Guinnepain MT, Barbaud A, Chosidow O, Roujeau JC, Lebrun-Vignes B, Descamps V. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010; 20:461-4.

-Jhaj R, Chaudhary D, Asati D, Sadasivam B. Fixed-drug Eruptions: What can we Learn from a Case Series? Indian J Dermatol. 2018; 63:332-337

-Heng YK, Yew YW, Lim DS, Lim YL. An update of fixed drug eruptions in Singapore. J Eur Acad Dermatol Venereol. 2015; 29:1539-44.

-Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med. 2011; 39:1521-32.

-Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study. Drug Saf. 2018. doi: 10.1007/s40264-018-0711-x.

-Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL Jr, Mushiroda T, Klein T, Gammal RS, Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018; 103:574-581.

-Lee TH, Lee CC, Ng CY, Chang MY, Chang SW, Fan PC, Chung WH, Tian YC, Chen YC, Chang CH. The influence of acute kidney injury on the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: The prognostic value of KDIGO staging. PLoS One. 2018; 13:e0203642.

-Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. Am J Med. 2016; 129:1221-1225.

-Chen CB, Abe R, Pan RY, Wang CW, Hung SI, Tsai YG, Chung WH. An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. J Immunol Res. 2018 Feb 13;2018:6431694. doi: 10.1155/2018/6431694.

-Cuestas D, Forero Y, Galvis I, Peñaranda E, Cortes C, Motta A, Mora S, Pérez C, Velasquez O, Puentes J. Drug reaction with eosinophilia and systemic symptoms (DRESS) and multiple organ dysfunction syndrome (MODS): one more reason for a new effective treatment against leishmaniasis. Int J Dermatol. 2018. doi: 10.1111/ijd.14126.

-Behera SK, Das S, Xavier AS, Selvarajan S. DRESS syndrome: a detailed insight. Hosp Pract (1995). 2018; 46:152-162.

-Wolfson AR, Zhou L, Li Y, Phadke NA, Chow OA, Blumenthal KG. Drug Rash Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module. J Allergy Clin Immunol Pract. 2018. pii: S2213-2198(18)30548-8.

-Podlipnik S, Castellanos-Moreira R, Florez-Enrich H, Arostegui JI, Mascaró JM Jr. Acute generalized exanthematous pustulosis and polyarthritis associated with a novel CARD14 mutation. Australas J Dermatol. 2018; 59:e70-e73.

–Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015; 73:843-8.

–Kley C, Murer C, Maul JT, Meier B, Anzengruber F, Navarini AA. Rapid Involution of Pustules during Topical Steroid Treatment of Acute Generalized Exanthematous Pustulosis. Case Rep Dermatol. 2017; 9:135-139.

-Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-grendelmeier P, Bircher A, Simon D. Urticaria and Angioedema: an Update on Classification and Pathogenesis. Clin Rev Allergy Immunol. 2018; 54:88-101.

-Sabroe RA. Acute urticaria. Immunol Allergy Clin North Am. 2014; 34:11-21.

-Abajian M, Schoepke N, Altrichter S, Zuberbier T, Maurer M. Physical urticarias and cholinergic urticaria. Immunol Allergy Clin North Am. 2014; 34:73-88.

-Du Thanh A. Urticaires inductibles et urticaires chroniques spontanées. Ann Dermatol Venereol. 2014; 141 Suppl 3:S570-99.

-Depetri F, Tedeschi A, Cugno M. Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment. Eur J Intern Med. 2018 Sep 13. pii: S0953-6205(18)30365-0

-Spickett G. Urticaria and angioedema. J R Coll Physicians Edinb. 2014; 44:50-4.

-Perera E, Sinclair R. Evaluation, diagnosis and management of chronic urticaria. Aust Fam Physician. 2014; 43:621-5.

-Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA. Urticaria: A comprehensive review: Treatment of chronic urticaria, special populations, and disease outcomes. J Am Acad Dermatol. 2018; 79:617-633.

-Giménez Arnau AM, Valero Santiago A, Bartra Tomás J, Jáuregui Presa I, Labrador-Horrillo M, Miquel Miquel FJ, Ortiz de Frutos J, Sastre J, Silvestre Salvador FJ, Ferrer Puga M. Therapeutic strategy according to the differing patient response profiles to omalizumab in chronic spontaneous urticaria. J Investig Allergol Clin Immunol. 2018 Sep 17:0. doi: 10.18176/jiaci.0323.

-Miller A, Chan M, Wiik A, Misbah SA, Luqmani RA. An approach to the diagnosis and management of systemic vasculitis. Clin Exp Immunol. 2010; 160:143-60.

-Micheletti RG, Werth VP. Small vessel vasculitis of the skin. Rheum Dis Clin North Am. 2015; 41:21-32.

-Sunderkötter C, Bonsmann G, Sindrilaru A, Luger T. Management of leukocytoclastic vasculitis. J Dermatolog Treat. 2005; 16:193-206.

-Arora A, Wetter DA, Gonzalez-Santiago TM, Davis MD, Lohse CM. Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2014; 89:1515-24.

-Baigrie D, Crane JS. Leukocytoclastic Vasculitis (Hypersensitivity Vasculitis). StatPearls Publishing; 2018 Jan-.2018 Feb 17.

-Barut K, Sahin S, Kasapcopur O. Pediatric vasculitis. Curr Opin Rheumatol. 2016; 28:29-38.

-Velter C, Lipsker D. Panniculites cutanées. Rev Med Interne. 2016; 37:743-750.

-Wick MR. Panniculitis: A summary. Semin Diagn Pathol. 2017; 34:261-272.

-Blake T, Manahan M, Rodins K. Erythema nodosum – a review of an uncommon panniculitis. Dermatol Online J. 2014; 20:22376.

-Passarini B, Infusino SD. Erythema nodosum. G Ital Dermatol Venereol. 2013; 148:413-7.

-Leung AKC, Leong KF, Lam JM. Erythema nodosum. World J Pediatr. 2018. doi: 10.1007/s12519-018-0191-1.

-Golisch KB, Gottesman SP, Segal RJ. Compression stockings as an effective treatment for erythema nodosum: Case series. Int J Womens Dermatol. 2017; 3:231-233.

-Sehrawat M, Dixit N, Sardana K, Malhotra P. Exploring the combination of SSKI and topical heparin in a case of erythema nodosum migrans. Dermatol Ther. 2018; 31:e12610.